501 related articles for article (PubMed ID: 34514812)
1. Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.
Odutayo A; da Costa BR; Pereira TV; Garg V; Iskander S; Roble F; Lalji R; Hincapié CA; Akingbade A; Rodrigues M; Agarwal A; Lawendy B; Saadat P; Udell JA; Cosentino F; Grant PJ; Verma S; Jüni P
J Am Heart Assoc; 2021 Sep; 10(18):e019918. PubMed ID: 34514812
[TBL] [Abstract][Full Text] [Related]
2. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
Duan XY; Liu SY; Yin DG
Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Täger T; Atar D; Agewall S; Katus HA; Grundtvig M; Cleland JGF; Clark AL; Fröhlich H; Frankenstein L
Heart Fail Rev; 2021 Nov; 26(6):1421-1435. PubMed ID: 32314085
[TBL] [Abstract][Full Text] [Related]
5. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis.
Tian L; Ai S; Zheng H; Yang H; Zhou M; Tang J; Liu W; Zhao W; Wang Y
Front Pharmacol; 2022; 13():986186. PubMed ID: 36506550
[TBL] [Abstract][Full Text] [Related]
10. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC
Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550
[TBL] [Abstract][Full Text] [Related]
11. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
Li X; Wu H; Peng H; Jiang H
Front Endocrinol (Lausanne); 2022; 13():1078686. PubMed ID: 36589800
[TBL] [Abstract][Full Text] [Related]
12. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
14. Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.
McNeill AM; Davies G; Kruger E; Kowal S; Reason T; Ejzykowicz F; Hannachi H; Cater N; McLeod E
Diabetes Ther; 2019 Apr; 10(2):473-491. PubMed ID: 30689140
[TBL] [Abstract][Full Text] [Related]
15. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
[TBL] [Abstract][Full Text] [Related]
16. Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?
Mukhopadhyay P; Sanyal D; Chatterjee P; Pandit K; Ghosh S
Endocr Pract; 2022 Aug; 28(8):795-801. PubMed ID: 35569736
[TBL] [Abstract][Full Text] [Related]
17. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
[TBL] [Abstract][Full Text] [Related]
18. Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials.
Tsai PC; Chuang WJ; Ko AM; Chen JS; Chiu CH; Chen CH; Yeh YH
Cardiovasc Diabetol; 2023 Mar; 22(1):57. PubMed ID: 36915157
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs.
Qiu M; Ding LL; Zhou HR
Am J Cardiovasc Drugs; 2022 Jan; 22(1):69-81. PubMed ID: 34231123
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes.
Siamashvili M; Davis SN
Expert Opin Pharmacother; 2021 Nov; 22(16):2181-2198. PubMed ID: 34388350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
